Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,099,633
  • Shares Outstanding, K 134,594
  • Annual Sales, $ 42,070 K
  • Annual Income, $ -130,300 K
  • EBIT $ -110 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.66
  • Price/Sales 24.70
  • Price/Cash Flow N/A
  • Price/Book 6.49

Options Overview Details

View History
  • Implied Volatility 188.83% ( -54.87%)
  • Historical Volatility 89.24%
  • IV Percentile 41%
  • IV Rank 20.96%
  • IV High 777.13% on 05/12/25
  • IV Low 32.80% on 09/04/25
  • Put/Call Vol Ratio 0.09
  • Today's Volume 38
  • Volume Avg (30-Day) 365
  • Put/Call OI Ratio 2.35
  • Today's Open Interest 7,121
  • Open Int (30-Day) 5,263

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.39
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.69 +22.12%
on 10/23/25
9.70 -15.77%
on 10/16/25
-0.53 (-6.09%)
since 10/14/25
3-Month
6.25 +30.72%
on 09/10/25
9.70 -15.77%
on 10/16/25
+1.25 (+18.06%)
since 08/14/25
52-Week
1.03 +693.20%
on 05/08/25
9.70 -15.77%
on 10/16/25
+4.25 (+108.42%)
since 11/14/24

Most Recent Stories

More News
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 8.17 (+5.83%)
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 8.17 (+5.83%)
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the...

TNGX : 8.17 (+5.83%)
Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 8.17 (+5.83%)
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 8.17 (+5.83%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 75.54 (-0.28%)
ARAY : 1.0400 (-6.31%)
KURA : 11.20 (+4.92%)
GTBP : 0.9206 (+26.14%)
TNGX : 8.17 (+5.83%)
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 8.17 (+5.83%)
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 8.17 (+5.83%)
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative...

TNGX : 8.17 (+5.83%)
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the...

TNGX : 8.17 (+5.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 9.23
2nd Resistance Point 8.79
1st Resistance Point 8.48
Last Price 8.17
1st Support Level 7.73
2nd Support Level 7.29
3rd Support Level 6.98

See More

52-Week High 9.70
Last Price 8.17
Fibonacci 61.8% 6.39
Fibonacci 50% 5.36
Fibonacci 38.2% 4.34
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar